End-stage renal disease in specific ethnic and racial groups: Risk factors and benefits of antihypertensive therapy

Archives of Internal Medicine

Volumn 158, Issue 7, 1998, Pages 793-800

  Powers, David R ^a   David Wallin, J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; NIFEDIPINE; THIAZIDE DIURETIC AGENT; VALSARTAN;

AMERICAN INDIAN; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC KIDNEY FAILURE; ETHNIC GROUP; FEMALE; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; DISEASE PROGRESSION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INDIANS, NORTH AMERICAN; KIDNEY FAILURE, CHRONIC; LIFE STYLE; RISK FACTORS; UNITED STATES;

EID: 2642614496     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.7.793     Document Type: Article

References (79)

1. US Renal Data System. USRDS 1993 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1993.
2. US Renal Data System. USRDS 1994 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1994.
3. US Renal Data System. USRDS 1995 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995.
4. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med. 1982;306:1276-1279.
5. Moyer JH, Heider C, Pevey K, Ford RV. The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function. Am J Med. 1958;24:177-192.
6. Tierney WM, McDonald CJ, Luft FC. Renal disease in hypertensive adults: effect of race and type II diabetes mellitus. Am J Kidney Dis. 1989;13:485-493.
7. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med. 1989;321:1074-1079.
8. Dasmahapatra A, Bale A, Raghuwanshi MP, et al. Incipient and overt diabetic nephropathy in African Americans with NIDDM. Diabetes Care. 1994;17:297-304.
9. Miller JM. Diabetes mellitus and hypertension in black and white populations. South Med J. 1986;79:1229-1235.
10. Hoy W, Light A, Megill D. Blood pressure in Navajo Indians and its association with type 2 diabetes and renal and cardiovascular disease. Am J Hypertens. 1994;7:321-328.
11. Bobbins DC, Knowler WC, Lee ET, et al. Regional differences in albuminuria among American Indians: an epidemic of renal disease. Kidney Int. 1996;49:557-563.
12. Sugarman JR. Prevalence of diagnosed hypertension among diabetic Navajo Indians. Arch Intern Med. 1990;150:359-362.
13. US Dept of Health, Education, and Welfare. National Health Survey: Hypertension and Hypertensive Heart Disease in Adults, US 1960-1962. Vital Health Stat 11. 1966;No. 13.
14. National Center for Health Statistics. Vital Statistics of the United States. 1979: Vol II, Mortality. Part A. Washington, DC: US Dept of Health and Human Services; 1984. Publication PHS 84-1101.
15. National High Blood Pressure Education Program Working Group. Report on hypertension and chronic renal failure. Arch Intern Med. 1991;151:1280-1287.
16. Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med. 1990;150:2073-2076.
17. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
18. Magee JH, Unger AM, Richardson DW. Changes in renal function associated with drug or placebo therapy of human hypertension. Am J Med. 1964;36:795-804.
19. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension. 1989;13(suppl I):I80-I93.
20. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med. 1989;320:684-688.
21. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis. 1988;12:285-290.
22. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. JAMA. 1992;268:3085-3091.
23. Whelton PK, Klag MJ. Hypertension as a risk factor for renal disease: review of clinical and epidemiological evidence. Hypertension. 1989;13 (suppl 1, pt 5):I19-I27.
24. Blythe WB, Maddux FW. Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980 to 1986. Am J Kidney Dis. 1991;18:33-37.
25. Luke RG. Can renal failure due to hypertension be prevented? Hypertension. 1991;18(suppl 3):I139-I142.
26. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984;26:861-868.
27. Honey GE, Pryse-Davies J, Robert DM. A survey of nephropathy in young diabetics. QJM. 1962;31:473-483.
28. Knowles HC Jr. Magnitude of the renal failure problem in diabetic patients. Kidney Int. 1974;(suppl 1):2-7.
29. Working Group on Hypertension in Diabetes. National High Blood Pressure Education Program. Statement on hypertension in diabetes mellitus: final report. Arch Intern Med. 1987;147:830-842.
30. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest. 1976;36:383-388.
31. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 1982;285:685-688.
32. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-1179.
33. Bauer JH, Reams GP. Do calcium antagonists protect the human hypertensive kidney? Am J Hypertens. 1989;2:173S-178S.
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
35. Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Int. 1982;21:730-738.
36. Nelson RG, Newman M, Knowler WC. Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 1988;31:730-736.
37. Nielsen S, Schmitz A, Rehling M, Mogensen CE. Systolic blood pressure relates to the rate of decline of glomerular filtration rate in type II diabetes. Diabetes Care. 1993;16:1427-1432.
38. Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus: a 14-year follow-up report on 195 patients. Arch Intern Med. 1992;152:1225-1229.
39. Chaiken RL, Palmisano J, Norton ME, et al. Interaction of hypertension and diabetes on renal function in black NIDDM subjects. Kidney Int. 1995;47:1697-1702.
40. Campese VM, Karubian F. Renal consequences of salt and hypertension. Semin Nephrol. 1991;11:549-560.
41. Williams GH, Hollenberg NK. Sodium-sensitive essential hypertension: emerging insights into pathogenesis and therapeutic implications. Contemp Nephrol. 1985;3:303-331.
42. +) intake in salt-sensitive (SS) patients with essential hypertension [abstract]. J Am Soc Nephrol. 1990;1:506A.
43. Zavaroni I, Coruzzi P, Bonini L, et al. Association between salt sensitivity and insulin concentrations in patients with hypertension. Am J Hypertens. 1995;8:855-858.
44. Edwards KGD. Why treat hyperlipidemia in patients with renal disease? Contrib Nephrol. 1981;18:3-10.
45. Moorhead JF, Chan MK, El-Nahas AM, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet. 1982;2:1309-1313.
46. Maschio G, Oldrizzi L, Rugiu C, Loschiavo C. Serum lipids in patients with chronic renal failure on long-term, protein-restricted diets. Am J Med. 1989;87(suppl 5):51N-54N.
47. Mulec H, Johnson SA, Bjorck S. Relation between serum cholesterol and diabetic nephropathy. Lancet 1990;335:1537-1538.
48. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia: a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int. 1994;45:S125-S131.
49. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman PO. Apolipoprotein-B containing lipoproteins and the progression of renal insufficiency. Nephron. 1993;63:279-285.
50. Naito H, Hirano T. Probucol suppresses the development of chronic renal failure in Dahl salt-sensitive rats: an animal model of spontaneous focal and segmental glomerulosclerosis. Nephron. 1994;67:125-126.
51. National Institutes of Health, National Heart, Lung, and Blood Institute. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
52. Ribstein J. Combined renal effects of overweight and hypertension. Hypertension. 1995;26:610-615.
53. Blair SN, Goodyear NN, Gibbons LW, Cooper KH. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA. 1989;252:487-490.
54. Maheswaran R, Gill JS, Davies P, Beevers DG. High blood pressure due to alcohol: a rapidly reversible effect. Hypertension. 1991;17:787-792.
55. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
56. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
57. Prisant LM, Carr AA. Antihypertensive drug therapy and insulin resistance. Am J Hypertens. 1992;5:775-777.
58. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia. 1988;31:415-420.
59. Ferriere M, Lachkar H, Richard JL, et al. Captopril and insulin sensitivity. Ann Intern Med. 1985;102:134-135.
60. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care. 1991;14 (suppl 4):39-47.
61. Pollare T, Lithell H, Morlin C, et al. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens. 1989;7:551-559.
62. Shieh S-M, Sheu WH-H, Shen DD-C, et al. Improvement in metabolic risk factors for coronary heart disease associated with cilazopril treatment. Am J Hypertens. 1992;5:506-510.
63. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. JAMA. 1993;270:713-724.
64. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
65. Abrams J, Vela BS, Coultras DB, Samaan SA, Malhatra D, Roche RJ. Coronary risk factors and their modification: lipids, smoking, hypertension, estrogen, and the elderly. Curr Probl Cardiol. 1995;20:533-610.
66. Grimm RH Jr, Leon AS, Hunninghake DB, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med. 1981;94:7-11.
67. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652-659.
68. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175-1179.
69. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 1982;285:685-688.
70. Keane WF, Shapiro BE. Renal protective effects of angiotensin-converting enzyme inhibition. Am J Cardiol. 1990;65:491-531.
71. Mimran A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouze J. Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertens. 1988;6:919-923.
72. Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452-458.
73. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
74. Jover B, Mimran A. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function. J Hypertens. 1994;12:S3-S9.
75. Epstein M. Calcium antagonists and the kidney: implications for renal protection. J Cardiovasc Pharmacol. 1991;18:S64-S70.
76. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861-867.
77. Lo M-W, Shahinfar S, Furtek CI, et at. Pharmacokinetics of losartan (MK-954 or DUP753) in patients with renal insufficiency. [abstract]. Clin Pharmacol Ther. 1993;53:160. Abstract PI-100.
78. Shaw W, Snavely D, Shahinfar S. Safety and efficacy of losartan (DuP 753, MK-954) in hypertensive patients with renal impairment [abstract]. J Am Soc Nephrol. 1994;5:567.
79. Weber MA, Laragh JH. Hypertension: steps forward and steps backward. Arch Intern Med. 1993;153:149-152.